Is axitinib/axitinib covered by medical insurance? Detailed explanation of medical insurance reimbursement policies and conditions

Axitinib/Axitinib is currently included in the national medical insurance directory in China, but its reimbursement indications are strictly limited. According to the content of the latest version of the medical insurance catalog in 2023, axitinib is included in the Class B medical insurance drug, which is suitable for adult patients with advanced renal cell carcinoma (RCC) who have received one type of systemic treatment in the past. In other words, only patients who meet the conditions for this indication can enjoy the medical insurance reimbursement policy in clinical practice. The prerequisites for medical insurance payment usually include the completion of standard diagnostic procedures and confirmation by multidisciplinary oncology consultation (MDT). At the same time, patients should be unable to tolerate or fail treatment with other targeted drugs such as sorafenib or sunitinib before they can use axitinib and apply for medical insurance reimbursement.

Axitinib currently sold in the Chinese market is Pfizer's original drug "Inlida". The common specifications are 1mg and 5mg tablets, with each box selling for several thousand yuan. After being included in medical insurance, the out-of-pocket proportion of patients in some areas can be reduced to about 20%-30%, which greatly reduces the financial burden. It is worth noting that there may be slight differences in local medical insurance policies, such as limited issuance cycles, designated hospital reimbursement, etc. It is recommended that patients consult the local medical insurance department or hospital pharmacy department for specific policies before use.

As the country's medical insurance coverage for innovative anticancer drugs continues to expand, the medical insurance coverage of axitinib has positive significance for improving the accessibility and continuity of kidney cancer treatment, and also reflects China's policy progress in promoting precision cancer treatment. For eligible patients, medical insurance reimbursement for axitinib can significantly reduce the financial burden and improve medication compliance and treatment effects.

Reference materials:https://en.wikipedia.org/wiki/Axitinib